The NAD(P)H:quinone oxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C. 1996

L T Hu, and J Stamberg, and S Pan
Division of Developmental Therapeutics, University of Maryland Cancer Center, University of Maryland School of Medicine, Baltimore 21201, USA.

Previously, we reported an association of mitomycin C resistance and a deficiency of NAD(P)H:quinone oxidoreductase (NQO1) in HCT 116-R30A cells, a subline derived from mitomycin C-sensitive HCT 116 cells. In HCT 116 cells, we found two mRNAs coding full-length cDNAs of NQO1 differing at codon 139, one with arginine (wild type), and one with tryptophan. Only the tryptophan 139 form of mRNA was detected in HCT 116-R30A cells. In addition, an exon 4 deleted mRNA of NQO1, a product of alternative splicing, was detected in both cell lines. Analysis by semiquantitative reverse transcription-PCR showed that NQO1 mRNA coding full-length cDNAs in HCT 116-R30A cells was 15% of that present in HCT 116 cells. A Mr 26,000 protein, representing the exon 4 deleted mRNA, was not detected by polyclonal anti-NQO1 in HCT 116 sublines. Recombinant plasmids of exon 4 deleted cDNA generated a Mr 26,000 protein without enzymatic activity in Escherichia coli but not in Cos7 cells. The function of exon 4 deleted mRNA is yet unknown. The rates of decay of all NQO1 mRNAs in HCT 116 and HCT 116-R30A cells were similar. DNA sequences of the promoter regions of the NQO1 gene (-837 bp) from both cell lines did not differ from each other or from the same region of the human liver NQO1 gene. Sequences of cis elements in the 837-bp region and mRNA stability could not account for the low expression of full-length mRNA in HCT 116-R30A cells. Southern blot analysis showed the size and the intensity of the NQO1 gene in the two cell lines to be similar. This result was confirmed by semiquantitative PCR analysis of a 450-bp fragment in the NQO1 gene containing codon 139 and the exon 4 region. Digestion of this PCR-amplified fragment by restriction enzyme MspI revealed that HCT 116 cells have two heterozygous NQO1 alleles, a wild-type and a tryptophan 139 form. The functional wild-type NQO1 allele was not detected in HCT 116-R30A cells. Sensitive and resistant cell lines each contained one normal and one abnormal chromosome 16. Loss of the wild-type NQO1 allele in HCT 116-R30A cells did not result from a loss of chromosome 16 or copies of the NQO1 gene. Alteration of factor(s) such as trans-acting factors and DNA methylation may be involved in the down-regulation of NQO1 in the mitomycin C-resistant HCT 116-R30A cells.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

L T Hu, and J Stamberg, and S Pan
January 1992, Cancer chemotherapy and pharmacology,
L T Hu, and J Stamberg, and S Pan
October 1997, Archives of biochemistry and biophysics,
L T Hu, and J Stamberg, and S Pan
June 1994, Biochemical pharmacology,
L T Hu, and J Stamberg, and S Pan
July 2005, Free radical biology & medicine,
L T Hu, and J Stamberg, and S Pan
March 2002, Cancer research,
L T Hu, and J Stamberg, and S Pan
June 2003, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!